Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.09 | N/A | -22.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.09 | N/A | -22.47% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over recent performance but remains committed to their strategic objectives. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current setbacks.
Kodiak Sciences reported a larger-than-expected loss per share, which contributed to a 2.23% decline in its stock price following the earnings announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's short-term outlook. Management's defensive tone suggests they are aware of the challenges ahead but are focused on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FOX CORP Class A
May 12, 2025